Mizuho lowered the firm’s price target on Cigna (CI) to $360 from $385 and keeps an Outperform rating on the shares in conjunction with publishing the firm’s 2025 outlook note for managed care, acute care, behavioral health, clinical labs, clinical research organizations, physician services, post-acute care, retail pharmacies, and surgery centers. The firm believes the two main themes for all of those subsectors is whether the demand environment is durable and what, if any, is the regulatory risk/benefit from the new administration in Washington, the analyst tells investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CI:
- Trump Trade: Federal funding plan endorsed by Trump fails
- Republicans spending package includes no PBM reform, Punchbowl says
- Trump Trade: Analyst says Trump win ‘not as positive as you’d think’ for Tesla
- Early notable gainers among liquid option names on December 18th
- PBMs took payments from manufacturers to allow free flow of opioids, NYT reports
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
